PURPOSE: To carry out an integrative profile of human pancreatic ductal adenocarcinoma (PDAC) to identify prognosis-significant genes and their related pathways. EXPERIMENTAL DESIGN: A concordant survival-based whole genome in silico array analysis of DNA copy number, and mRNA and miRNA expression in 25 early-stage PDAC was carried out. A novel composite score simultaneously integrated gene expression with regulatory mechanisms to identify the signature genes with the most levels of prognosis-significant evidence. The predominant signaling pathways were determined via a pathway-based approach. Independent patient cohorts (n = 148 and 42) were then used as in vitro validation of the array findings. RESULTS: The composite score identified 171 genes in which expressions were able to define two prognosis subgroups (P = 3.8e-5). Eighty-eight percent (151 of 171) of the genes were regulated by prognosis-significant miRNAs. The phosphoinositide 3-kinase/AKT pathway and SRC signaling were densely populated by prognosis-significant genes and driven by genomic amplification of SRC and miRNA regulation of p85α and CBL. On tissue microarray validation (n = 148), p85α protein expression was associated with improved survival for all patients (P = 0.02), and activated P-SRC (Y418) was associated shorter survival for patients with low-grade histology tumors (P = 0.04). Interacting P-SRC and p85α revealed that they define two distinct PDAC patient subgroups (P = 0.0066). Furthering the importance of these pathways, CBL protein expression was associated with improved survival (P = 0.03) on a separate cohort (n = 42). CONCLUSIONS: These pathways and related genes may represent putative clinical biomarkers and possible targets of individualized therapy in the distinct patient subgroups they define.
PURPOSE: To carry out an integrative profile of humanpancreatic ductal adenocarcinoma (PDAC) to identify prognosis-significant genes and their related pathways. EXPERIMENTAL DESIGN: A concordant survival-based whole genome in silico array analysis of DNA copy number, and mRNA and miRNA expression in 25 early-stage PDAC was carried out. A novel composite score simultaneously integrated gene expression with regulatory mechanisms to identify the signature genes with the most levels of prognosis-significant evidence. The predominant signaling pathways were determined via a pathway-based approach. Independent patient cohorts (n = 148 and 42) were then used as in vitro validation of the array findings. RESULTS: The composite score identified 171 genes in which expressions were able to define two prognosis subgroups (P = 3.8e-5). Eighty-eight percent (151 of 171) of the genes were regulated by prognosis-significant miRNAs. The phosphoinositide 3-kinase/AKT pathway and SRC signaling were densely populated by prognosis-significant genes and driven by genomic amplification of SRC and miRNA regulation of p85α and CBL. On tissue microarray validation (n = 148), p85α protein expression was associated with improved survival for all patients (P = 0.02), and activated P-SRC (Y418) was associated shorter survival for patients with low-grade histology tumors (P = 0.04). Interacting P-SRC and p85α revealed that they define two distinct PDACpatient subgroups (P = 0.0066). Furthering the importance of these pathways, CBL protein expression was associated with improved survival (P = 0.03) on a separate cohort (n = 42). CONCLUSIONS: These pathways and related genes may represent putative clinical biomarkers and possible targets of individualized therapy in the distinct patient subgroups they define.
Authors: Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Jennifer P Morton; Saadia A Karim; Kathryn Graham; Paul Timpson; Nigel Jamieson; Dimitris Athineos; Brendan Doyle; Colin McKay; Man-Yeung Heung; Karin A Oien; Margaret C Frame; T R Jeffry Evans; Owen J Sansom; Valerie G Brunton Journal: Gastroenterology Date: 2010-03-17 Impact factor: 22.682
Authors: E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: Eric A Collisson; Anguraj Sadanandam; Peter Olson; William J Gibb; Morgan Truitt; Shenda Gu; Janine Cooc; Jennifer Weinkle; Grace E Kim; Lakshmi Jakkula; Heidi S Feiler; Andrew H Ko; Adam B Olshen; Kathleen L Danenberg; Margaret A Tempero; Paul T Spellman; Douglas Hanahan; Joe W Gray Journal: Nat Med Date: 2011-04-03 Impact factor: 53.440
Authors: Giorgos L Papadopoulos; Martin Reczko; Victor A Simossis; Praveen Sethupathy; Artemis G Hatzigeorgiou Journal: Nucleic Acids Res Date: 2008-10-27 Impact factor: 16.971
Authors: Paul A Toste; Luyi Li; Brian E Kadera; Andrew H Nguyen; Linh M Tran; Nanping Wu; David L Madnick; Sanjeet G Patel; David W Dawson; Timothy R Donahue Journal: J Surg Res Date: 2015-03-06 Impact factor: 2.192
Authors: V Coothankandaswamy; S Cao; Y Xu; P D Prasad; P K Singh; C P Reynolds; S Yang; J Ogura; V Ganapathy; Y D Bhutia Journal: Br J Pharmacol Date: 2016-10-18 Impact factor: 8.739
Authors: Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-12-10 Impact factor: 4.254
Authors: Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc Journal: Mol Cancer Ther Date: 2013-11-26 Impact factor: 6.261
Authors: Michael A Badgley; Daniel M Kremer; H Carlo Maurer; Kathleen E DelGiorno; Ho-Joon Lee; Vinee Purohit; Irina R Sagalovskiy; Alice Ma; Jonathan Kapilian; Christina E M Firl; Amanda R Decker; Steve A Sastra; Carmine F Palermo; Leonardo R Andrade; Peter Sajjakulnukit; Li Zhang; Zachary P Tolstyka; Tal Hirschhorn; Candice Lamb; Tong Liu; Wei Gu; E Scott Seeley; Everett Stone; George Georgiou; Uri Manor; Alina Iuga; Geoffrey M Wahl; Brent R Stockwell; Costas A Lyssiotis; Kenneth P Olive Journal: Science Date: 2020-04-03 Impact factor: 47.728
Authors: Michael D Arensman; Phillip Nguyen; Kathleen M Kershaw; Anna R Lay; Claire A Ostertag-Hill; Mara H Sherman; Michael Downes; Christopher Liddle; Ronald M Evans; David W Dawson Journal: Mol Cancer Res Date: 2015-07-29 Impact factor: 5.852